{"cluster": 48, "subcluster": 39, "abstract_summ": "Measurement of these markers might assist clinicians to monitor and predict the severity and prognosis of COVID-19.Background: Most patients infected by SARS-CoV-2 have favourable outcomes, however some develop severe disease which may progress to acute respiratory distress syndrome, multi-organ failure, and death.Conclusions: Lower lymphocyte counts are significantly associated with more severe disease in patients with SARS-CoV-2 infection.CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.Calculation of metamedians from the two papers classifying severe disease according to death alone gave 1.1 1x109/L lymphocytes (95% CI 1.0-1.1) for \u201csurvivors\u201d (n=163) and 0.63 1x109/L lymphocytes (95% CI 0.60-0.63) for \u201cnon-survivors\u201d (n=253) of SAR-CoV-2 disease.A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48\u00d710(9)/L; 95% CI, -57 to -39\u00d710(9)/L. In the four studies (n=1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6).", "title_summ": "Can we predict the severity of COVID-19 with a routine blood test?Lymphocytopaenia is associated with severe SARS-CoV-2 disease: A Systematic Review and Meta-Analysis of Clinical DataLymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysisThrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysisLymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis", "title_abstract_phrases": "Measurement of these markers might assist clinicians to monitor and predict the severity and prognosis of COVID-19.Lymphocytopaenia is associated with severe SARS-CoV-2 disease: A Systematic Review and Meta-Analysis of Clinical DataBackground: Most patients infected by SARS-CoV-2 have favourable outcomes, however some develop severe disease which may progress to acute respiratory distress syndrome, multi-organ failure, and death.Conclusions: Lower lymphocyte counts are significantly associated with more severe disease in patients with SARS-CoV-2 infection.Calculation of metamedians from the two papers classifying severe disease according to death alone gave 1.1 1x109/L lymphocytes (95% CI 1.0-1.1) for \u201csurvivors\u201d (n=163) and 0.63 1x109/L lymphocytes (95% CI 0.60-0.63) for \u201cnon-survivors\u201d (n=253) of SAR-CoV-2 disease.CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48\u00d710(9)/L; 95% CI, -57 to -39\u00d710(9)/L. In the four studies (n=1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6)."}